{
  "docId": "019de076-e431-717d-85d5-60fbb8c86744",
  "docSlug": "9614dd2dbfdf83d72e770ebfe5753af3",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 42,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a 2x2 grid layout to summarize key company metrics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-e431-717d-85d5-60fbb8c86744/3",
  "deckHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744",
  "deckJsonHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744.json",
  "deckAnchorHref": "/decks/019de076-e431-717d-85d5-60fbb8c86744#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.45,
        "x": 0.5,
        "y": 0.15
      },
      "kind": "framework",
      "text": null,
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "135efe4e-026b-4485-9b10-52a32af9dac7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.06,
        "y": 0.45
      },
      "kind": "list",
      "text": "Parallel lead programs for ROS1+ and ALK+ NSCLC in global clinical development. Proven discovery capabilities: Third program for HER2+ NSCLC in IND enabling studies & active research pipeline",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21e5e965-9eaa-429c-9fe7-757778e4fe2e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.15,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "metric",
      "text": "Growing team (90+ FTEs)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77c9fe18-4df2-49b0-b056-d692d67446b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.1,
        "x": 0.8,
        "y": 0.74
      },
      "kind": "paragraph",
      "text": "Nasdaq listed",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2249c502-9c3c-4769-af18-5f72faf71fe5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.78,
        "y": 0.34
      },
      "kind": "paragraph",
      "text": "Hybrid operations with offices in Cambridge, MA",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61b71e70-f463-447a-8461-d397313f26b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.55,
        "y": 0.74
      },
      "kind": "paragraph",
      "text": "Cash runway expected into 2027",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed2fe3bd-127d-42a9-85a8-6f968a706a74",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.38,
        "x": 0.06,
        "y": 0.24
      },
      "kind": "title",
      "text": "Precisely Targeted Therapies for patients with cancer",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba898089-9dda-46f4-b9c7-675b8b190447",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.22,
        "y": 0.08
      },
      "kind": "title",
      "text": "Nuvalent AT-A-GLANCE",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d7721bdb-3ab5-471c-b14d-f91e382e8c50",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "604ce47b-d1f6-4b40-8de1-07931f28e356",
      "evidence": "title/action-title: Precisely Targeted Therapies for patients with cancer",
      "confidence": 0.7
    },
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "8af90262-6fd7-40a5-8738-2efd7ddb26bb",
      "evidence": "list/bullet: Parallel lead programs for ROS1+ and ALK+ NSCLC in global clinical development.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "matrix-2x2",
      "slug": null,
      "matchId": "cc1d5603-012e-4e5a-b033-ca915e906ad0",
      "evidence": "The slide organizes four key company facts into a 2x2 grid layout.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}